Payment overview · 2025
General Payments
$1,991.47
105 reported records · 23 companies
Healthcare provider profile · identity verified
Kevin Musto, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PITTSTON, PA · NPI 1669884607
Verified facts
What the public records show
CMS Open Payments records show Kevin Musto, M.D. received $1,991.47 in general payments during 2025 across 105 reported records.
PFIZER INC. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Paxlovid, Rexulti, Rybelsus, Synthroid, Trelegy Ellipta, Ubrelvy, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 755 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 755 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lantus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $405.29 | 20.4% | 31 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $302.69 | 15.2% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $202.49 | 10.2% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $174.73 | 8.8% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $152.31 | 7.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $117.00 | 5.9% | 6 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $100.14 | 5.0% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $75.35 | 3.8% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $58.36 | 2.9% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $51.38 | 2.6% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $50.11 | 2.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.36 | 2.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $41.81 | 2.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $38.86 | 1.9% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $32.64 | 1.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $24.65 | 1.2% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $21.59 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.44 | 1.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.32 | 0.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.86 | 0.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $13.92 | 0.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $13.70 | 0.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.47 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,991.47 | 105 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $318.63 | 25 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $158.59 | 15 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $152.78 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $152.31 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $143.17 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $138.15 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $135.63 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $109.70 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $89.90 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $86.66 | 6 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $86.66 | 6 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $86.66 | 6 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $78.67 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $59.45 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $58.36 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $57.76 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $57.55 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.47 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.47 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $51.38 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $50.11 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $46.36 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $45.84 | 3 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $42.14 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.82 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $41.81 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $38.86 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $32.64 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $31.61 | 2 | 2025 |
Source payment records
|
|||||
| XGEVA Normalized: xgeva |
Biological | Amgen Inc. | $31.61 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $24.65 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $21.59 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 29 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 755 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 131 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 53 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 175 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 126 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
175 | 38 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
755 | 89 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
126 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
755 | 89 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
53 | 51 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1561 | 358 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1403 | 290 |
| Amlodipine Besylate | Amlodipine Besylate | 952 | 233 |
| Omeprazole | Omeprazole | 814 | 207 |
| Metoprolol Succinate | Metoprolol Succinate | 789 | 176 |
| Eliquis | Apixaban | 755 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 672 | 169 |
| Furosemide | Furosemide | 668 | 142 |
| Potassium Chloride | Potassium Chloride | 638 | 136 |
| Lisinopril | Lisinopril | 632 | 158 |
| Gabapentin | Gabapentin | 626 | 137 |
| Alprazolam | Alprazolam | 589 | 121 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 576 | 156 |
| Metoprolol Tartrate | Metoprolol Tartrate | 564 | 120 |
| Losartan Potassium | Losartan Potassium | 524 | 117 |
| Famotidine | Famotidine | 455 | 110 |
| Simvastatin | Simvastatin | 438 | 103 |
| Metformin Hcl | Metformin Hcl | 424 | 101 |
| Hydrochlorothiazide | Hydrochlorothiazide | 402 | 95 |
| Montelukast Sodium | Montelukast Sodium | 372 | 110 |
| Tamsulosin Hcl | Tamsulosin Hcl | 353 | 81 |
| Prednisone | Prednisone | 347 | 225 |
| Clopidogrel | Clopidogrel Bisulfate | 309 | 67 |
| Citalopram Hbr | Citalopram Hydrobromide | 308 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 295 | 70 |
| Atenolol | Atenolol | 294 | 71 |
| Warfarin Sodium | Warfarin Sodium | 289 | 28 |
| Allopurinol | Allopurinol | 285 | 73 |
| Trazodone Hcl | Trazodone Hcl | 282 | 64 |
| Sertraline Hcl | Sertraline Hcl | 268 | 57 |
| Carvedilol | Carvedilol | 264 | 56 |
| Lorazepam | Lorazepam | 253 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 249 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 241 | 91 |
| Torsemide | Torsemide | 231 | 74 |
| Donepezil Hcl | Donepezil Hcl | 216 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 203 | 72 |
| Doxycycline Hyclate | Doxycycline Hyclate | 198 | 136 |
| Escitalopram Oxalate | Escitalopram Oxalate | 189 | 46 |
| Glipizide Er | Glipizide | 188 | 41 |
| Levetiracetam | Levetiracetam | 175 | 25 |
| Metformin Hcl Er | Metformin Hcl | 175 | 44 |
| Synthroid | Levothyroxine Sodium | 175 | 38 |
| Azithromycin | Azithromycin | 171 | 135 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 170 | 33 |
| Januvia | Sitagliptin Phosphate | 170 | 22 |
| Tramadol Hcl | Tramadol Hcl | 167 | 50 |
| Buspirone Hcl | Buspirone Hcl | 161 | 41 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 160 | 126 |
| Celecoxib | Celecoxib | 160 | 54 |
| Mirtazapine | Mirtazapine | 159 | 41 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 154 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 154 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 152 | 108 |
| Clonidine Hcl | Clonidine Hcl | 144 | 41 |
| Tradjenta | Linagliptin | 142 | 16 |
| Memantine Hcl | Memantine Hcl | 134 | 26 |
| Jardiance | Empagliflozin | 131 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 130 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 126 | 26 |
| Finasteride | Finasteride | 124 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 122 | 28 |
| Glipizide | Glipizide | 122 | 20 |
| Xarelto | Rivaroxaban | 121 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 120 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 117 | 27 |
| Spironolactone | Spironolactone | 116 | 26 |
| Ezetimibe | Ezetimibe | 112 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 111 | 89 |
| Pregabalin | Pregabalin | 109 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 105 | 53 |
| Fluoxetine Hcl | Fluoxetine Hcl | 104 | 24 |
| Meloxicam | Meloxicam | 102 | 29 |
| Nystatin | Nystatin | 102 | 56 |
| Alendronate Sodium | Alendronate Sodium | 100 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 98 | 23 |
| Bupropion Xl | Bupropion Hcl | 98 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 95 | 28 |
| Meclizine Hcl | Meclizine Hcl | 95 | 29 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 92 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 92 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 90 | 49 |
| Baclofen | Baclofen | 88 | 38 |
| Glimepiride | Glimepiride | 85 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 84 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 26 |
| Divalproex Sodium | Divalproex Sodium | 82 | 19 |
| Sucralfate | Sucralfate | 81 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 23 |
| Ibuprofen | Ibuprofen | 78 | 26 |
| Levofloxacin | Levofloxacin | 76 | 52 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 75 | 15 |
| Midodrine Hcl | Midodrine Hcl | 75 | 16 |
| Labetalol Hcl | Labetalol Hcl | 73 | 13 |
| Risperidone | Risperidone | 73 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 72 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 72 | 38 |
| Valsartan | Valsartan | 72 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 13 |
| Aripiprazole | Aripiprazole | 71 | 14 |
| Bumetanide | Bumetanide | 71 | 14 |
| Klor-Con 10 | Potassium Chloride | 71 | suppressed |
| Olanzapine | Olanzapine | 71 | 14 |
| Fluconazole | Fluconazole | 69 | 44 |
| Oxycodone Hcl | Oxycodone Hcl | 68 | 20 |
| Cephalexin | Cephalexin | 65 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 21 |
| Ozempic | Semaglutide | 64 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 31 |
| Entresto | Sacubitril/Valsartan | 62 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 62 | 19 |
| Ondansetron Odt | Ondansetron | 62 | 47 |
| Clonazepam | Clonazepam | 61 | 19 |
| Methylprednisolone | Methylprednisolone | 60 | 51 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | 11 |
| Diazepam | Diazepam | 58 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | 13 |
| Myrbetriq | Mirabegron | 56 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 55 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 17 |
| Cholestyramine | Cholestyramine (With Sugar) | 53 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 53 | 51 |
| Methocarbamol | Methocarbamol | 51 | 15 |
| Amoxicillin | Amoxicillin | 50 | 39 |
| Irbesartan | Irbesartan | 50 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 48 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 44 | 28 |
| Nifedipine Er | Nifedipine | 43 | suppressed |
| Lovastatin | Lovastatin | 40 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Mounjaro | Tirzepatide | 39 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Metolazone | Metolazone | 38 | 17 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 37 | 18 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 37 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 35 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Primidone | Primidone | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Dexamethasone | Dexamethasone | 32 | 31 |
| Raloxifene Hcl | Raloxifene Hcl | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 31 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 31 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Lactulose | Lactulose | 30 | 11 |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Latanoprost | Latanoprost | 30 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 29 | 29 |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 29 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 22 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 14 |
| Insulin Aspart Flexpen | Insulin Aspart | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Colchicine | Colchicine | 24 | 12 |
| Mupirocin | Mupirocin | 24 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Insulin Lispro | Insulin Lispro | 23 | suppressed |
| Nystop | Nystatin | 23 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Calcium Acetate | Calcium Acetate | 21 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 20 | 20 |
| Dutasteride | Dutasteride | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 19 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 19 | 11 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 12 |
| Ramelteon | Ramelteon | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | 12 |
| Nadolol | Nadolol | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Novolog | Insulin Aspart | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Budesonide | Budesonide | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 15 |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | 12 |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Azathioprine | Azathioprine | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Metaxalone | Metaxalone | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | 12 |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 13 | 13 |
| Propafenone Hcl Er | Propafenone Hcl | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Asmanex | Mometasone Furoate | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 12 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,991.47 · 105 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, AUSTEDO XR, Auvelity, BREZTRI, CAMZYOS, CAPLYTA, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, INGREZZA, JARDIANCE, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, QULIPTA, REXULTI, Rybelsus, SYNTHROID, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Vest Therapy Und, Wegovy, XGEVA, XIFAXAN, ZAVZPRET, ZEPBOUND | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error